Clinical Research

The purpose of the INOVATE-HF study is to demonstrate the long-term safety and efficacy of vagus nerve stimulation with the CardioFit® system for the treatment of subjects with Heart Failure.

Please refer to www.clinicaltrials.gov identifier NCT01303718 for more information.

The aim of this study is to assess whether increasing oral doses of Riociguat are safe and improve the well-being, symptoms and outcome in patients with pulmonary hypertension associated with left ventricular systolic dysfunction

The purposes of this study are to confirm that the Freedom Driver System is a suitable pneumatic driver for clinically stable TAH-t subjects, and that patients and lay caregivers can be trained to manage the Freedom Driver System safely outside the hospital.

Please refer to www.clinicaltrials.gov identifier NCT00733447 for more information.

Long-term Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension (SERAPHIN OL)

The main objective of the AC 055 303/SERAPHIN OL study, which will follow the AC 055 302/SERAPHIN study, will be to assess the long-term safety and tolerability of ACT 064992 in patients with symptomatic PAH.

This study is closed to enrollment and in the follow-up phases.

Please refer to www.clinicaltrials.gov identifier NCT00667823 for more information

ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension

This Phase 3, international, multicenter, open-label study will monitor the long-term safety of ambrisentan in subjects with PH. The available ambrisentan doses for this study are 2.5, 5, or 10 mg once daily (qd); the approved doses in the United States, Canada, and the European Union are 5 and 10 mg ambrisentan qd. Investigators will be able to adjust ambrisentan dose as clinically indicated. Ambrisentan can be increased or decreased in one-step intervals, with a minimum of 4 weeks between dose adjustments. Subjects receiving other therapies for PH that are not contraindicated for concomitant use with ambrisentan are permitted to enroll in this study and continue to receive such therapies.

This study is closed to enrollment and in the follow-up phase.

Please refer to www.clinicaltrials.gov identifier: NCT00777920 for more information.